(NAII) Natural Alternatives - Ratings and Ratios
Contract Manufacturing, Tablets, Capsules, Powders, Licensing
NAII EPS (Earnings per Share)
NAII Revenue
Description: NAII Natural Alternatives
Natural Alternatives International, Inc. is a contract manufacturer and supplier of nutritional supplements, leveraging its expertise to provide customized solutions to clients across various distribution channels, including direct sales, e-commerce, and retail. The companys capabilities extend beyond manufacturing to include strategic partnering services such as product formulation, clinical study design, and regulatory compliance, making it a one-stop-shop for companies seeking to bring nutritional supplements to market.
The companys product portfolio includes a range of formats, such as capsules, tablets, and powders, and it has developed proprietary ingredients like CarnoSyn and SR CarnoSyn, a beta-alanine ingredient used in performance-enhancing supplements. NAIIs client base includes companies operating in the nutritional supplements space, and its services are designed to support clients across the product lifecycle, from formulation to delivery.
Analyzing the technical data, we observe that NAIIs stock price has been trending below its 200-day moving average, indicating a potential downtrend. However, the stock is currently trading above its 20-day and 50-day moving averages, suggesting some short-term bullishness. The ATR indicates a relatively high level of volatility, which could be a concern for investors. Considering the fundamental data, NAIIs market capitalization is approximately $20.15 million, and the company is currently unprofitable, as indicated by the absence of P/E ratios and a negative RoE.
Based on the technical and fundamental data, a potential forecast for NAII is that the stock may continue to experience volatility in the short term, potentially trading within a range of $2.61 to $6.88. However, given the companys negative RoE and lack of profitability, a more likely scenario is that the stock will remain under pressure unless the company can demonstrate significant improvements in its financial performance. A potential catalyst for NAIIs stock could be a turnaround in its financials, potentially driven by increased demand for its contract manufacturing services or the success of its proprietary ingredients. If NAII can achieve profitability, we might see the stock price re-rate, potentially targeting the 52-week high of $6.88.
NAII Stock Overview
| Market Cap in USD | 25m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 1987-03-13 |
NAII Stock Ratings
| Growth Rating | -70.4% |
| Fundamental | 16.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -41.6% |
| Analyst Rating | - |
NAII Dividends
Currently no dividends paidNAII Growth Ratios
| Growth Correlation 3m | 80.1% |
| Growth Correlation 12m | -82.3% |
| Growth Correlation 5y | -89.4% |
| CAGR 5y | -14.22% |
| CAGR/Max DD 5y | -0.16 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | -33.90 |
| Beta | -0.289 |
| Volatility | 49.71% |
| Current Volume | 0.3k |
| Average Volume 20d | 2k |
| Stop Loss | 3.5 (-6.2%) |
| Signal | -1.04 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-8.23m TTM) > 0 and > 6% of Revenue (6% = 7.53m TTM) |
| FCFTA -0.03 (>2.0%) and ΔFCFTA -7.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 28.06% (prev 33.88%; Δ -5.83pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -130.0k > Net Income -8.23m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.94m) change vs 12m ago 1.28% (target <= -2.0% for YES) |
| Gross Margin 5.72% (prev 7.91%; Δ -2.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 81.44% (prev 78.43%; Δ 3.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -12.98 (EBITDA TTM -6.11m / Interest Expense TTM 826.0k) >= 6 (WARN >= 3) |
Altman Z'' 3.32
| (A) 0.23 = (Total Current Assets 58.5m - Total Current Liabilities 23.3m) / Total Assets 154.9m |
| (B) 0.43 = Retained Earnings (Balance) 66.6m / Total Assets 154.9m |
| (C) -0.07 = EBIT TTM -10.7m / Avg Total Assets 154.1m |
| (D) 0.85 = Book Value of Equity 66.4m / Total Liabilities 78.3m |
| Total Rating: 3.32 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 15.99
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -16.71% = -5.0 |
| 3. FCF Margin -3.60% = -1.35 |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda -2.13 = -2.50 |
| 6. ROIC - WACC -15.32% = -12.50 |
| 7. RoE -10.34% = -1.72 |
| 8. Rev. Trend -70.96% = -3.55 |
| 9. Rev. CAGR -19.66% = -2.50 |
| 10. EPS Trend -74.94% = -1.87 |
| 11. EPS CAGR -44.06% = -2.50 |
What is the price of NAII shares?
Over the past week, the price has changed by -6.28%, over one month by -1.84%, over three months by +11.01% and over the past year by -31.31%.
Is Natural Alternatives a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NAII is around 3.20 USD . This means that NAII is currently overvalued and has a potential downside of -14.21%.
Is NAII a buy, sell or hold?
What are the forecasts/targets for the NAII price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 3.4 | -8.3% |
Last update: 2025-08-23 04:45
NAII Fundamental Data Overview
CCE Cash And Equivalents = 10.6m USD (Cash And Short Term Investments, last quarter)
P/S = 0.196
P/B = 0.3196
Beta = 0.64
Revenue TTM = 125.5m USD
EBIT TTM = -10.7m USD
EBITDA TTM = -6.11m USD
Long Term Debt = 8.70m USD (from longTermDebt, last quarter)
Short Term Debt = 4.32m USD (from shortTermDebt, last quarter)
Debt = 13.0m USD (Calculated: Short Term 4.32m + Long Term 8.70m)
Net Debt = 36.8m USD (from netDebt column, last quarter)
Enterprise Value = 27.0m USD (24.6m + Debt 13.0m - CCE 10.6m)
Interest Coverage Ratio = -12.98 (Ebit TTM -10.7m / Interest Expense TTM 826.0k)
FCF Yield = -16.71% (FCF TTM -4.51m / Enterprise Value 27.0m)
FCF Margin = -3.60% (FCF TTM -4.51m / Revenue TTM 125.5m)
Net Margin = -6.56% (Net Income TTM -8.23m / Revenue TTM 125.5m)
Gross Margin = 5.72% ((Revenue TTM 125.5m - Cost of Revenue TTM 118.3m) / Revenue TTM)
Tobins Q-Ratio = 0.41 (Enterprise Value 27.0m / Book Value Of Equity 66.4m)
Interest Expense / Debt = 1.89% (Interest Expense 246.0k / Debt 13.0m)
Taxrate = 21.0% (US default)
NOPAT = -10.7m (EBIT -10.7m, no tax applied on loss)
Current Ratio = 2.51 (Total Current Assets 58.5m / Total Current Liabilities 23.3m)
Debt / Equity = 0.17 (Debt 13.0m / last Quarter total Stockholder Equity 76.6m)
Debt / EBITDA = -2.13 (Net Debt 36.8m / EBITDA -6.11m)
Debt / FCF = -2.89 (Debt 13.0m / FCF TTM -4.51m)
Total Stockholder Equity = 79.6m (last 4 quarters mean)
RoA = -5.31% (Net Income -8.23m, Total Assets 154.9m )
RoE = -10.34% (Net Income TTM -8.23m / Total Stockholder Equity 79.6m)
RoCE = -12.13% (Ebit -10.7m / (Equity 79.6m + L.T.Debt 8.70m))
RoIC = -11.56% (NOPAT -10.7m / Invested Capital 92.7m)
WACC = 3.75% (E(24.6m)/V(37.6m) * Re(4.95%)) + (D(13.0m)/V(37.6m) * Rd(1.89%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -10.0 | Cagr: -1.28%
Discount Rate = 4.95% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -4.51m)
Revenue Correlation: -70.96 | Revenue CAGR: -19.66%
Rev Growth-of-Growth: 37.07
EPS Correlation: -74.94 | EPS CAGR: -44.06%
EPS Growth-of-Growth: 61.21
Additional Sources for NAII Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle